Medication records usually emphasize the dose of each active drug. When several formulations share a solvent, the relevant exposure may be distributed across more than one administration. Bjur and colleagues reported this problem in a critically ill adolescent receiving treatment for refractory myoclonic status epilepticus.
How the shared exposure arose
The patient received several formulations containing propylene glycol, including lorazepam, phenobarbital and pentobarbital. Acidosis and hemodynamic instability developed during the course of treatment. The authors reviewed the combined solvent exposure and considered other explanations, including sepsis. A serum specimen taken before dialysis contained 35 mg/dL of propylene glycol, adding direct evidence of solvent exposure to the clinical timeline. The patient’s condition improved after several interventions, including stopping a propylene glycol-containing medication and starting hemodialysis.
What the case supports in a record review
Identify the actual product, solvent concentration, administered volume and infusion timing for every relevant medication. Then compare the estimated solvent timeline with laboratory values and organ function. Active-drug doses alone omit that shared exposure.
The report concerns one patient receiving several simultaneous interventions. It does not establish a universal toxicity threshold or allow the improvement to be assigned to a single intervention from timing alone.
Leave a Reply